We are live on ! Find out more
SPRO icon

Spero Therapeutics
SPRO

89 hedge funds and large institutions have $370M invested in Spero Therapeutics in 2020 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 34 increasing their positions, 23 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% more capital invested

Capital invested by funds: $186M → $370M (+$184M)

85% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 13

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

48% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 23

14% more funds holding

Funds holding: 78 → 89 (+11)

5.53% more ownership

Funds ownership: 64.67% → 70.19% (+5.5%)

26% less call options, than puts

Call options by funds: $1.5M | Put options by funds: $2.04M

Holders
89
Holders Change
+11
Holders Change %
+14.1%
% of All Funds
1.57%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.05%
New
24
Increased
34
Reduced
23
Closed
13
Calls
$1.5M
Puts
$2.04M
Net Calls
-$539K
Net Calls Change
-$142K

Top Buyers

Rank Fund Capital Flow
1
BI
BVF Inc
California
+$14M
2
BlackRock
BlackRock
New York
+$10.2M
3
Ameriprise
Ameriprise
Minnesota
+$4.14M
4
Morgan Stanley
Morgan Stanley
New York
+$3.87M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$3.15M

Top Sellers

Rank Fund Capital Flow
1
ACM
Aquilo Capital Management
California
-$8.81M
2
NHAS
Novo Holdings A/S
Denmark
-$5.52M
3
AI
Alphabet Inc
California
-$3.47M
4
AIC
AWM Investment Company
New York
-$1.96M
5
SB
Samsara BioCapital
California
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
New York State Common Retirement Fund
26
New York State Common Retirement Fund
New York
$1.14M +$206K +13,200 +29%
Millennium Management
27
Millennium Management
New York
$1.13M -$1.13M -72,512 -56%
Charles Schwab
28
Charles Schwab
California
$1.01M +$255K +16,377 +46%
Russell Investments Group
29
Russell Investments Group
United Kingdom
$1M -$1.01M -64,761 -56%
Alyeska Investment Group
30
Alyeska Investment Group
Illinois
$962K -$786K -50,398 -50%
Stifel Financial
31
Stifel Financial
Missouri
$950K -$20K -1,280 -3%
Two Sigma Investments
32
Two Sigma Investments
New York
$841K +$676K +43,373 New
Wells Fargo
33
Wells Fargo
California
$811K +$131K +8,424 +25%
Goldman Sachs
34
Goldman Sachs
New York
$807K +$160K +10,256 +33%
Cambridge Investment Research Advisors
35
Cambridge Investment Research Advisors
Iowa
$667K +$537K +34,423 New
Citadel Advisors
36
Citadel Advisors
Florida
$633K +$177K +11,328 +53%
California State Teachers Retirement System (CalSTRS)
37
California State Teachers Retirement System (CalSTRS)
California
$600K +$137K +8,760 +40%
California Public Employees Retirement System
38
California Public Employees Retirement System
California
$593K -$42K -2,694 -8%
DADC
39
D.A. Davidson & Co
Montana
$582K +$7.79K +500 +2%
PPA
40
Parametric Portfolio Associates
Washington
$494K +$397K +25,455 New
SPA
41
Sentinel Pension Advisors
Massachusetts
$458K +$368K +23,615 New
Los Angeles Capital Management
42
Los Angeles Capital Management
California
$432K -$133K -8,550 -28%
State of Wisconsin Investment Board
43
State of Wisconsin Investment Board
Wisconsin
$401K -$40.5K -2,600 -11%
Two Sigma Advisers
44
Two Sigma Advisers
New York
$375K -$32.7K -2,100 -10%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$373K +$71.2K +4,568 +31%
GG
46
Gofen & Glossberg
Illinois
$339K +$117K +7,500 +75%
BCM
47
Bourgeon Capital Management
Connecticut
$297K +$239K +15,341 New
Deutsche Bank
48
Deutsche Bank
Germany
$294K +$108K +6,916 +84%
UBS Group
49
UBS Group
Switzerland
$278K +$216K +13,847 +2,769%
SC
50
Scholtz & Company
Connecticut
$268K +$7.48K +480 +4%
1
2
3 4 5

SPRO Hedge Fund Activity: Q4 2020 in Review

89 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Spero Therapeutics (SPRO) for Q4 2020, worth a combined $370M — up 99% from $186M a quarter earlier.

Buyers outnumbered sellers: 24 funds opened new SPRO positions and 13 closed out — a net gain of 11 holders — while 34 added to existing stakes and 23 trimmed.

The largest buyer was BVF Inc, adding an estimated $14M. The largest seller was Aquilo Capital Management, cutting an estimated $8.81M.

  • 89 institutional investors held Spero Therapeutics (SPRO) as of Q4 2020, up from 78 in Q3 2020.
  • Funds reported $370M of Spero Therapeutics stock for Q4 2020, up 99% quarter-over-quarter.
  • 24 funds opened new Spero Therapeutics positions in Q4 2020 and 13 closed out, a net change of +11 holders.
  • The largest Spero Therapeutics buyer in Q4 2020 was BVF Inc, an estimated $14M added.
  • The largest Spero Therapeutics seller in Q4 2020 was Aquilo Capital Management, an estimated $8.81M sold.

Based on aggregated 13F filings for Q4 2020.